Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab

Clinical Cancer Research

Volumn 13, Issue 8, 2007, Pages 2392-2399

  Berdeja, Jesús G ^a   Hess, Allan ^b   Lucas, David M ^c   O'Donnell, Paul ^d   Ambinder, Richard F ^b   Diehl, Louis F ^b   Carter Brookins, Denise ^b   Newton, Susan ^b   Flinn, Ian W ^b,e  

^a LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; INTERLEUKIN 2; LYMPHOKINE; RITUXIMAB;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER REGRESSION; CANCER RELAPSE; CELL ACTIVITY; CELL CULTURE; CELL TRANSFER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KILLER CELL; LEUKAPHERESIS; PERIPHERAL LYMPHOCYTE; PILOT STUDY; PRIORITY JOURNAL;

ADOPTIVE TRANSFER; AMINO ACID SUBSTITUTION; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; COMBINED MODALITY THERAPY; HUMANS; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LEUKAPHERESIS; LYMPHOMA, B-CELL; LYMPHOMA, MANTLE-CELL; RECEPTORS, IGG; RECURRENCE;

EID: 34247847914     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1860     Document Type: Article

References (39)

1. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457-66.
2. Reff M, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
3. Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 2003;30:S3-8.
4. Badger CA, Anasetti C, Davis J, Bernstein ID. Treatment of malignancy with unmodified antibody. Pathol Immunopathol Res 1987;6:419-34.
5. Ghielmini M, Rufibach K, Salles G, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005;16:1675-82.
6. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002;99:754-8.
7. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7.
8. Maloney DG. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol 2005;23:6421-8.
9. Jakobisiak M, Janowska-Wieczorek A, Dobaczewska H, et al. Decreased antibody-dependent cellular cytotoxicity in various types of leukaemia in man. Scand J Haematol 1981;27:181-5.
10. Saijo N, Shimizu E, Irimajiri N, et al. Analysis of natural killer activity and antibody-dependent cellular cytotoxicity in healthy volunteers and in patients with primary lung cancer and metastatic pulmonary tumors. J Cancer Res Clin Oncol 1982;102:195-214.
11. Lindemann A, Hermann F, Oster W, Mertelsmann R. Lymphokine activated killer cells. Blut 1989;59: 375-84.
12. Weber JS, Yang JC, Topalian SL, Schwartzentruber D, White CA, Rosenberg SA. The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma. J Clin Oncol 1992;10:33-40.
13. Margolin KA, Aronson FR, Sznol M, et al. Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma. J Immunother 1991;10:214-20.
14. Bernstein ZP, Vaickus L, Friedman N, et al. Interleukin-2 lymphokine-activated killer cell therapy of non-Hodgkin's lymphoma and Hodgkin's disease. J Immunother 1991;10:141-6.
15. Shiloni E, Eisenthal A, Sachs D. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin-2. J Immunol 1987;138:1992-8.
16. Ortaldo JR, Mason A, Overton R. Lymphokine-activated killer cells: analysis of progenitors and effectors. J Exp Med 1986;164:1193-205.
17. Schultz KR, Klarnet JP, Peace DJ, et al. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells. Cancer Res 1990; 50:5421-5.
18. Senba T, Kurori M, Arakawa F, et al. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model. Anticancer Res 1998;18:17-24.
19. Watanabe M, Kubota T, Kitajima M, Hakomorim S. Synergetic effect of interleukin-2 and cellular cytotoxicity against a novel tumor-associated carbohydrate antigen Le(a)/Le(a) (dimeric Le(a)) mediated by monoclonal antibody NCC-ST-421 in adoptive immunization using SCID mice. Cancer Immunol Immunother 1993;37:245-50.
20. Pendurthi TK, Parker R, Schlom J, Primus FJ. Lymphokine-activated killer cell cytotoxicity against human colon carcinomas enhanced by monoclonal antibody D612. Int J Cancer 1990;46:1021-8.
21. Pendurthi TK, Schlom J, Primus FJ. Human lymphokine-activated killer cells augment immunotherapy of human colon carcinoma xenografts with monoclonal antibody D612. J Immunother 1991;10: 2-12.
22. Gill I, Agah R, Hu E, Mazumder A. Synergistic anti-tumor effects of interleukin-2 and the monoclonal Lym-1 against human Burkitt's lymphoma cells in vitro and in vivo. Cancer Res 1989;49:5377-9.
23. Masucci G, Wersall P, Nielsen J, Nielsen HK, Wigzell H, Mellstedt H. Lymphokine activated killer cells in antibody dependent cellular cytotoxicity using MAb 17-1A: a combination of potential usefulness in tumor therapy. Hybridoma 1989;8:507-16.
24. Kawase I, Komuta K, Hara H, et al. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin-2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Cancer Res 1988;48:1173-9.
25. Eisenthal A, Cameron RB, Uppenkamp I, Rosenberg SA. Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases. Cancer Res 1988;48:7140-5.
26. Flinn IW, O'Donnell PV, Goodrich A, et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000;6:628-32.
27. Clark JW, Smith JW, Steis RG, et al. Interleukin-2 and LAK cell therapy: analysis of a bolus IL-2 and a continuous infusion IL-2 regimen. Cancer Res 1990; 50:7343-50.
28. Miura Y, Thoburn CJ, Bright EC, et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 2004;104:2187-93.
29. Miura Y, Thoburn CJ, Bright EC, Chen W, Nakao S, Hess AD. Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): interleukin 10 and interferon γ may be critical mediators for the development of autologous GVHD. Blood 2002;100:2650-8.
30. Ettinghausen SE, Lipford EH III, Mule JJ, Rosenberg SA. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells. J Immunol 1985;135:3623-35.
31. Muul LM, Director EP, Hyatt CL, Rosenberg SA. Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy. J Immunol Methods 1986;88:265-75.
32. Horton SA, Oldham RK, Yannelli JR. Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin 2. Cancer Res 1990; 50:1686-92.
33. Golay J, Manganini M, Facchinetti V, et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 2003;88: 1002-12.
34. Gluck WL, Hurst D, Yuen A, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004;10:2253-64.
35. Eisenbeis CF, Grainger A, Fischer B, et al. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Clin Cancer Res 2004;10:6101-10.
36. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998;160:1212-8.
37. Farag S, Flinn IW, Modali R, Lehman TA, Young D, Byrd JC. Fc-γRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 2004;103:1472-4.
38. Friedberg JW, Neuberg D, Gribben JG, et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 2002;117: 828-34.
39. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153-64.